In a phase 1/2 trial, 35 high-risk patients with blood cancer who underwent reduced-intensity allogeneic stem-cell tranplantation who took the CCR5 chemokine receptor blocker maraviroc had lower rates of acute (grade II–IV) graft-versus-host disease (GVHD) than were expected. At 100 days, only 14·7% of patients had developed acute visceral GVHD (no cases were noted in the gut or liver), with few side-effects.

Fulltext